Defining Nonresponse to PBC Treatment: Curbside Consults Podcast
02/24/25 • 18 min
How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:
- How and when to measure treatment response
- Evidence-based goals of therapy
- Considerations for second-line treatment
- New agents for second-line treatment: PPAR agonists
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:
- How and when to measure treatment response
- Evidence-based goals of therapy
- Considerations for second-line treatment
- New agents for second-line treatment: PPAR agonists
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
Previous Episode
PBC Perspectives: A Patient and HCP in Conversation
In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:
- The chronic nature of PBC
- Going beyond biochemical markers to assess and address symptoms such as fatigue and pruritus
- The importance of referral to patient support groups
Presenters:
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director, General Gastroenterology and Hepatology
Weill Cornell Medical College
New York, New York
Maria G. Morais, RN
VP Patient Advocacy
Canadian PBC Society
Toronto, Canada
To learn more, see the program Hear Me: Patient Perspectives on PBC
Next Episode
Evaluating and Managing PBC Symptoms: Curbside Consults Podcast
In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:
- Strategies and tools for assessing pruritus
- Nonpharmacologic and pharmacologic management of pruritus
- Second-line agents and their impact on pruritus
- Investigational treatments for pruritus
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/cco-medical-specialties-podcast-642721/defining-nonresponse-to-pbc-treatment-curbside-consults-podcast-86192679"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to defining nonresponse to pbc treatment: curbside consults podcast on goodpods" style="width: 225px" /> </a>
Copy